- Significant mean reduction of 26.5% in LDL-C with bempedoic acid vs. placebo in pooled analysis of people who cannot tolerate statins 1 - - Analysis by sex showed bempedoic acid significantly lowered LDL-C at week 12 in males and females * vs. placebo 2 - ANN ARBOR, Mich., Nov.
ANN ARBOR, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the pricing of $250.0 million aggregate principal amount of 4.00% Convertible Senior Subordinated Notes due 2025 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers
ANN ARBOR, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Subordinated Notes due 2025 (the “notes”) in a private offering (the
ANN ARBOR, Mich., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 4, 2020, the Compensation Committee of Esperion’s Board of Directors granted 33,663 restricted stock units (RSUs) to 24 new colleagues under Esperion’s 2017 Inducement Equity Incentive
– Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL ® (bempedoic acid) and NEXLIZET ® (bempedoic acid and ezetimibe) tablets – – U.S. Product Revenue Increased Five-fold During the Third Quarter – – ESPERION Partner Daiichi Sankyo Europe Launches NILEMDO™ (bempedoic acid) and
ANN ARBOR, Mich., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in three upcoming virtual conferences during the month of November. Event: Credit Suisse 29 th Annual Virtual Healthcare Conference Date: November 9,
ANN ARBOR, Mich., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2020 financial results after the close of the U.S. financial markets on Monday, November 2, 2020. Following the release, company management will host a webcast and conference
- NEXLETOL® exhibited a 22% mean reduction in LDL-C levels in patients with Heterozygous Familial Hypercholesterolemia at week-12 - ANN ARBOR, Mich., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced results of pooled data from two of the company’s Phase 3 trials were
ANN ARBOR, Mich., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the launch of “Break the Cycle with NEXLETOL”, a national direct-to-consumer (DTC) campaign aimed at broadening awareness of NEXLETOL® (bempedoic acid) Tablets and the never-ending patient cycle of diet,
ANN ARBOR, Mich., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of September. Event: Citi 15 th Annual Biopharma Conference Date: September 9, 2020 Format: 1:1